PMID: 8590774Aug 1, 1995Paper

Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer

International Journal of Hematology
T SuzukiK Fukutake

Abstract

Most factor VIII inhibitors are developed at an early age and in patients with severe type of hemophilia A. We report a case of newly developed factor VIII inhibitor in a 60-year-old patient with mild hemophilia A who had been treated with several kinds of factor VIII concentrates. The patient was treated with a total of 103,580 units of recombinant factor VIII concentrate by continuous and bolus infusions for the open surgery of sigmoid colon cancer. On the 95th postoperative day, the patient had right low limb muscle bleeding and was infused with 1,000 units of recombinant factor VIII concentrate for three days. Subsequently, the level of factor VIII inhibitor in the patient's plasma was 2 Bethesda units (BU)/ml. Since then numerous subcutaneous hemorrhages developed, but an adequate hemostatic effect was not obtained even with the administration of a high dose of recombinant factor VIII concentrate. The patient was switched to bypass therapy using human plasma-derived factor VIIa concentrate, which showed a favorable hemostatic effect.

Citations

Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·A SharathkumarM D Carcao
Aug 30, 2005·Annals of the New York Academy of Sciences·Ch von AuerI Scharrer
Nov 13, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·A L Dunn
Feb 16, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·A GringeriUNKNOWN Emoclot15 Study Members

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.